ALNEV — Neovacs SA Share News
0.000.00%
Last trade - 00:00- €0.01m
- -€0.03m
- €0.16m
Brief: Neovacs H1 Operating Loss Narrows To 4.6 Million Euros
Brief: Neovacs Appoints Vincent Serra As CEO
AstraZeneca lupus drug shows promise after set-back last year (updated)
Brief: Neovacs To Present Pre-Clinical Results Of IFNalpha Kinoid
Brief: Neovacs Issues Second And Additional Tranche Of ORNANE (Convertible Bonds) For A Total Amount Of 3.3 Million Euros
Brief: Neovacs To Present Pre-Clinical Results Of Its Vaccine Candidate IL-4 / IL-13 Kinoid
Brief: Neovacs Announces Results Of Its Phase IIb Clinical Study Of IFnalpha Kinoid In Lupus
Brief: Neovacs: new supply agreement with German group Biosyn to diversify sourcing of KLH
Brief: Neovacs FY Operating Loss Narrows To 13.1 Million Euros
Brief: Neovacs To Present Preclinical Results Of IL-4 / IL-13 Kinoid At Keystone Congress
Brief: Neovacs Announces Clinical Advisory Board Meeting To Design Phase III Study For IFNalpha Kinoide In Lupus
Brief: Neovacs Presents Phase IIb Ifnalpha Kinoid Clinical Study Results
Brief: Neovacs Secures Financing From French National Research Agency
Brief: Neovacs And Centurion Pharma Continue Their Collaboration In Lupus
Brief: Neovacs: In Vivo Proof Of Concept Success For Il-4/Il-13 Kinoid
Brief: Neovacs H1 Net Loss Narrows to 6.1 Million Euros
Brief: Neovacs Continues To Develop IFNα Kinoid With CKD Pharmaceuticals
Brief: Neovacs: Biosense Global Exercises Option To Acquire Exclusive License For IFNalpha Kinoid In China
Stellar Biotech: Jumps on positive study news for protein product